

## Supporting Information

# New Meroterpenoid Derivatives from the Pomegranate-Derived Endophytic Fungus *Talaromyces purpureogenus*

Alaa Anwar <sup>1</sup>, Mohamed S. Elnaggar <sup>1,2,\*</sup>, Ahmed M. Elissawy <sup>1,3</sup>, Nehal Ibrahim <sup>1</sup>, Attila Mándi <sup>4</sup>, Tibor Kurtán <sup>4</sup>, Zhen Liu <sup>5</sup>, Sherweit H. El-Ahmady <sup>1</sup> and Rainer Kalscheuer <sup>2,\*</sup>

<sup>1</sup> Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Abbassia, Cairo 11566, Egypt; alaa.a.husain@pharma.asu.edu.eg (A.A.); aelissawy@pharma.asu.edu.eg (A.M.E.); nehal.sabry@pharma.asu.edu.eg (N.I.); selahmady@pharma.asu.edu.eg (S.H.E.-A.)


<sup>2</sup> Institute of Pharmaceutical Biology and Biotechnology, Heinrich Heine University, Universitätsstrasse 1, 40225 Düsseldorf, Germany

<sup>3</sup> Center for Drug Discovery Research and Development, Faculty of Pharmacy, Ain-Shams University, Abbassia, Cairo 11566, Egypt

<sup>4</sup> Department of Organic Chemistry, University of Debrecen, P.O. Box 400, 4002 Debrecen, Hungary; mandi.attila@science.unideb.hu (A.M.); kurtan.tibor@science.unideb.hu (T.K.)

<sup>5</sup> Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha 410013, China; zhenfeizi0@sina.com

\* Correspondence: mohamed.s.elnaggar@pharma.asu.edu.eg (M.S.E.); rainer.kalscheuer@uni-duesseldorf.de (R.K.); Tel.: +20-1005647840 (M.S.E.); +49-211-81-14180 (R.K.)



**Figure S1.** High resolution -ve ESIMS of compound 1




Figure S2.  $^1\text{H}$  NMR spectrum of compound **1** in  $\text{CDCl}_3$







Figure S3. APT NMR spectrum of compound **1** in  $\text{CDCl}_3$




**Figure S4.** HSQC spectrum of compound **1** in CDCl<sub>3</sub>




**Figure S5.** COSY spectrum of compound **1** in CDCl<sub>3</sub>



**Figure S6.** HMBC spectrum of compound **1** in CDCl<sub>3</sub>



**Figure S7.** NOESY spectrum of compound **1** in  $\text{CDCl}_3$



(A)

## Mass Spectrum SmartFormula Report

### Analysis Info


Analysis Name D:\Data\Spektren 2022\KAL22HR000143.d  
 Method tune\_low\_new.m  
 Sample Name Elnaggar TP-7-9-9 (CH<sub>3</sub>OH)  
 Comment

Acquisition Date 10/24/2022 3:33:03 PM

Operator PT  
 Instrument maXis 288882.20213

### Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active	Set Capillary	4000 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1500 m/z	Set Collision Cell RF	600.0 Vpp	Set Divert Valve	Source



(B)

**Figure S8.** (A) Low resolution +ve/-ve ESIMS of compound 2. (B) High resolution +ve ESIMS of compound 2.




Figure S9.  $^1\text{H}$  NMR spectrum of compound **2** in  $\text{CDCl}_3$






Figure S10. APT NMR spectrum of compound **2** in  $\text{CDCl}_3$







**Figure S11.** HSQC spectrum of compound **2** in  $\text{CDCl}_3$



**Figure S12.** COSY spectrum of compound **2** in  $\text{CDCl}_3$



**Figure S13.** HMBC spectrum of compound **2** in  $\text{CDCl}_3$



**Figure S14.** NOESY spectrum of compound **2** in  $\text{CDCl}_3$




Figure S15.  $^1\text{H}$  NMR spectrum of compound **2** in  $\text{DMSO}-d_6$




Figure S16. NOESY spectrum of compound **2** in  $\text{DMSO}-d_6$